Zymeworks BC Inc.
Clinical trials sponsored by Zymeworks BC Inc., explained in plain language.
Zymeworks BC Inc.
ZYME
NASDAQ
A biopharmaceutical company developing bispecific antibody therapeutics for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug ZW191 targets Hard-to-Treat cancers in early trial Results expected Dec 2026 (estimated)
- New Antibody-Drug conjugate ZW251 enters first human trials for Hard-to-Treat cancers Results expected Sep 2027 (estimated)